compliance effort. The Agencies recognize that the staggered implementation date imposes a shorter adjustment period on banks that are less automated. Additionally, the Agencies received recommendations from the industry, subsequent to the publication of the policy in the **Federal Register**, to delay the implementation of the policy for all financial institutions to December 31, 2000.

In order to allow all institutions to meet the implementation deadlines within the same time period, including those that are not highly automated, the FFIEC is modifying the effective date. This notice extends the implementation date for manual changes to the December 31, 2000, Call Report or Thrift Financial Report. Institutions that have already implemented manual changes to meet the revised guidelines may continue to use their revised policies and procedures, but are not required to do so.

Dated: November 17, 1999.

Keith J. Todd,

Executive Secretary, Federal Financial Institutions Examination Council.

[FR Doc. 99–30433 Filed 11–22–99; 8:45 am]

BILLING CODE 6210–01–P; 6714–01–P; 6720–01–P; 4810–33–P

GENERAL ACCOUNTING OFFICE

[Document Nos. JFMIP–SR–99–12 and 99–13]

Joint Financial Management Improvement Program (JFMIP)—Federal Financial Management System Requirements (FFMSR)

AGENCY: Joint Financial Management Improvement Program (JFMIP), GAO.

ACTION: Notice of document availability.

SUMMARY: The JFMIP is seeking public comment on two exposure drafts titled, (1) ''Guaranteed Loan System Requirements,'' and (2) ''Grant Financial System Requirements,'' both dated October 19, 1999. The guaranteed loan document is being issued to update a December 1993 document. This is the first time that a requirements document has been issued for grants. The drafts incorporate: (1) statutory and regulatory changes; (2) technological changes; and (3) JFMIP documentation changes. The document is designed to provide financial managers with Governmentwide mandatory requirements for financial systems in order to process and record financial events effectively and efficiently, and to provide complete, timely, reliable, and consistent information for decision makers and the public.

DATES: Comments are due on both documents by Friday, December 17, 1999.

ADDRESSES: Copies of the exposure draft have been mailed to Agency Senior Financial Officials and are available on the JFMIP website: *www.financenet.gov/fed/jfmip/jfmip.htm*.

Comments should be addressed to JFMIP, 441 G Street NW., Room 3111, Washington, DC 20548.

JFMIP Relocation: We are working to relocate JFMIP, by the middle of November, 1999, to 1990 K St., Suite 430. We are working closely with the GAO, where JFMIP is currently located, to ensure a smooth transition of U.S. Postal and electronic mail services. When the exact date of the location is known, information will be posted on the JFMIP Homepage.

FOR FURTHER INFORMATION CONTACT: Dennis Mitchell, 202–512–5994 or via Internet: *mitchelld.jfmip@gao.gov*.

SUPPLEMENTARY INFORMATION: The Federal Financial Management Improvement Act (FFMIA) of 1996 mandated that agencies implement and maintain systems that comply substantially with Federal financial management systems requirements, applicable Federal accounting standards, and the U.S. Government Standard General Ledger at the transaction level. The FFMIA statute codified the JFMIP financial systems requirements documents as a key benchmark that agency systems must meet in order to be substantially in compliance with systems requirements provisions under FFMIA. To support the requirements outlined in the FFMIA, we are updating requirements documents that are obsolete and publishing additional requirements documents.

Comments received will be reviewed and the exposure draft will be revised as necessary. Publication of the final requirements will be mailed to agency senior financial officials and will be available on the JFMIP website.

Karen Cleary Alderman,

Executive Director, Joint Financial Management Improvement Program.

[FR Doc. 99–30434 Filed 11–22–99; 8:45 am]

BILLING CODE 1610–02–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

The 2000 FDA Science Forum—FDA and the Science of Safety: New Perspectives

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

The Food and Drug Administration (FDA), Office of Science is announcing the following meeting entitled ''The 2000 FDA Science Forum—FDA and the Science of Safety: New Perspectives.'' The forum is devoted to the presentation and sharing of data, knowledge, and ideas among the diverse disciplines of risk management. The forum will bring FDA scientists together with industry, academia, government agencies, consumer groups, and the public to explore the scientific and practical issues related to the safety evaluation and risk management of FDA-regulated products.

Date and Time: The forum will be held on Monday, February 14, 2000, from 8:30 a.m. to 7 p.m., and Tuesday, February 15, 2000, from 8:30 a.m. to 4:30 p.m.

Location: Washington Convention Center, rms. 29 to 32 (lower level), and Hall C (upper level), 900 Ninth St. NW., Washington, DC 20001.

Contact: American Association of Pharmaceutical Scientists, 703–548–3000, or Donna L. Mentch, Food and Drug Administration, Office of Science (HF–33), 5600 Fishers Lane, Rockville, MD 20857, 301–827–3340, e-mail: dmentch@oc.fda.gov.

Registration: Attendees may register from 7 a.m. to 5 p.m. on February 14, 2000, and from 8 a.m. to 1 p.m. on February 15, 2000. Fees, registration, and program information are also available at www.aaps.org/edumeet/fdasf/index.html or from the contact persons listed above. Attendance will be limited; therefore, interested parties are encouraged to register early.

SUPPLEMENTARY INFORMATION: The meeting is cosponsored by FDA's Office of Science, the American Association of Pharmaceutical Scientists, FDA's Office of Women's Health, and FDA's Chapter of Sigma Xi the Scientific Research Society. Speakers and panelists will address emerging issues in the safety assessment of foods, human and animal drugs, biologics, and medical devices. Plenary lectures and discussion groups will provide perspectives on the following topics:

(1) Walking and Talking: The Art and Science of Risk Communication;

(2) Contemporary Issues in Risk Assessment;

(3) Postmarket Surveillance—Beyond Passive Surveillance;

(4) The Food Safety Initiative—The Risk Perspective;

(5) New Scientific Perspectives: Women's Health and the Science of Gender Differences; and

(6) Risk Assessment in Action.

If you need special accommodations due to a disability, please contact the American Association of Pharmaceutical Scientists at least 3 weeks in advance.

Dated: November 17, 1999.

William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation.

[FR Doc. 99–30527 Filed 11–22–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Blood Donor Suitability Workshop; Public Workshop

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

The Food and Drug Administration (FDA) is announcing a public workshop entitled ''Blood Donor Suitability Workshop.'' The purpose of the public workshop is to provide an open forum for discussion of specific donor suitability issues associated with donor deferrals.

Date and Time: The public workshop will be held on December 9, 1999, 8 a.m. to 5 p.m.

Location: The public workshop will be held at 5630 Fishers Lane, rm. 1066, Rockville, MD 20857.

Contact: Joseph Wilczek, Center for Biologics Evaluation and Research (HFM–350), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–6129, FAX 301–827–2843.

For information regarding the public workshop and registration: Therese Burke, Laurel Consulting Group, 1815 Fort Meyer Dr., suite 300, Arlington, VA 22209, 703–351–7676, FAX 703–528–0716, E-mail: tburke@lcgnet.com.

Registration: Early registration is recommended on or before November 26, 1999. Mail or fax registration information (including name, title, firm name, address, telephone, and fax number) to Therese Burke (address above). Registration at the site will be done on a space available basis on the day of the workshop, beginning at 7:30 a.m. There is no registration fee for the workshop. If you need special accommodations due to a disability, please contact Therese Burke at least 7 days in advance.

Agenda: FDA is holding a public workshop to gather scientific data on specific donor suitability issues affecting donor deferrals and to evaluate how these donor deferrals may affect the nation's blood supply. The three key topics to be discussed at the workshop include: (1) Donor deferral registries, including deferral registries that are used in-house, at mobile collection sites, as well as registries shared by several facilities; (2) minimum donor weight and adjustment of blood volume based on body weight; and (3) deferral of donors who have a history of cancer.

Transcripts: Transcripts of the public workshop may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A-16, Rockville, MD 20857, approximately 15 working days after the public workshop at a cost of 10 cents per page. The public workshop transcript will also be available on the Center for Biologics Evaluation and Research website at http://www.fda.gov/cber/minutes/workshop-min.htm.

Dated: November 17, 1999.

William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation.

[FR Doc. 99–30522 Filed 11–22–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Workshop on Implementation of Nucleic Acid Testing; Public Workshop

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

The Food and Drug Administration (FDA) is announcing a public workshop entitled ''Implementation of Nucleic Acid Testing.'' The purpose of the public workshop is to discuss the progress in implementation of nucleic acid testing for screening blood and plasma donors.

Date and Time: The public workshop will be held on December 14, 1999, from 8 a.m. to 5 p.m.

Location: The public workshop will be held at the National Institutes of Health, Clinical Center, Bldg. 10, Jack Masur Auditorium, 9000 Rockville Pike, Bethesda, MD 20892.

Contacts:

For information regarding this notice: Joseph Wilczek, Center for Biologics Evaluation and Research (HFM–350), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–6129, FAX 301–827–2843.

For information regarding registration: Jennifer Gormley, Laurel Consulting Group, 1815 Fort Meyer Dr., suite 300, Arlington, VA 22209, 703–351–7676, FAX: 703–528–0716, e-mail: jgormley@lcgnet.com.

Registration: Early registration is recommended on or before Friday, November 26, 1999. Mail or fax registration information (including name, title, firm name, address, telephone, and fax number) to Jennifer Gormley (address above). Registration at the site will be on a space available basis on the day of the workshop, beginning at 7:30 a.m. There is no registration fee for the workshop. If you need special accommodations due to a disability, please contact Jennifer Gormley at least 7 days in advance.

Agenda: FDA is holding a public workshop to evaluate progress in the implementation of nucleic acid testing (NAT) for screening blood and plasma donors. The goals of the public workshop are to: (1) Examine technological advances and current experience with testing plasma pools for hepatitis C virus (HCV), hepatitis B virus (HBV) and human immunodeficiency virus (HIV); (2) discuss issues in the implementation of NAT; (3) evaluate the application of NAT to other transmitted viruses; and (4) monitor progress towards single donation testing. The scientific information obtained from these discussions will provide FDA with a better understanding of the utility of nucleic acid testing of plasma pools in reducing the residual risk of infectious disease transmission from window period donations. In addition, FDA will be able to evaluate progress towards single unit testing by NAT for future implementation in screening blood and plasma donors.

Transcripts: Transcripts of the public workshop may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A–16, Rockville, MD 20857, approximately 15 working days after the meeting at a cost of 10 cents per page. In addition, the transcript will be placed on the FDA web site at www.fda.gov/cber/minutes/workshop-min.htm.